Tags : Neuromyelitis Optica Spectrum

Alexion’s Soliris (eculizumab) Receives FDA’s Approval for Anti-Aquaporin-4 Antibody Positive

Shots: The approval is based on P-III PREVENT study results assessing Soliris vs PBO in patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive The P-III PREVENT study results: @48wks. & @144wks. relapse free patients (98% & 96% vs 63% & 45%); relapse free patients without receiving IST @144wks. (100% vs […]Read More